vs
Embecta Corp.（EMBC）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是PREFORMED LINE PRODUCTS CO的1.5倍（$261.2M vs $173.1M），Embecta Corp.净利率更高（16.9% vs 4.9%，领先12.0%），PREFORMED LINE PRODUCTS CO同比增速更快（3.6% vs -0.3%），Embecta Corp.自由现金流更多（$16.6M vs $11.8M），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
EMBC vs PLPC — 直观对比
营收规模更大
EMBC
是对方的1.5倍
$173.1M
营收增速更快
PLPC
高出3.9%
-0.3%
净利率更高
EMBC
高出12.0%
4.9%
自由现金流更多
EMBC
多$4.8M
$11.8M
两年增速更快
PLPC
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $173.1M |
| 净利润 | $44.1M | $8.4M |
| 毛利率 | 61.9% | 29.8% |
| 营业利润率 | 31.9% | 6.8% |
| 净利率 | 16.9% | 4.9% |
| 营收同比 | -0.3% | 3.6% |
| 净利润同比 | — | -19.3% |
| 每股收益（稀释后） | $0.74 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCPLPC
| Q4 25 | $261.2M | $173.1M | ||
| Q3 25 | $264.0M | $178.1M | ||
| Q2 25 | $295.5M | $169.6M | ||
| Q1 25 | $259.0M | $148.5M | ||
| Q4 24 | $261.9M | $167.1M | ||
| Q3 24 | $286.1M | $147.0M | ||
| Q2 24 | $272.5M | $138.7M | ||
| Q1 24 | $287.2M | $140.9M |
净利润EMBCPLPC
| Q4 25 | $44.1M | $8.4M | ||
| Q3 25 | $26.4M | $2.6M | ||
| Q2 25 | $45.5M | $12.7M | ||
| Q1 25 | $23.5M | $11.5M | ||
| Q4 24 | $0 | $10.5M | ||
| Q3 24 | $14.6M | $7.7M | ||
| Q2 24 | $14.7M | $9.4M | ||
| Q1 24 | $28.9M | $9.6M |
毛利率EMBCPLPC
| Q4 25 | 61.9% | 29.8% | ||
| Q3 25 | 60.0% | 29.7% | ||
| Q2 25 | 66.7% | 32.7% | ||
| Q1 25 | 63.4% | 32.8% | ||
| Q4 24 | 60.0% | 33.3% | ||
| Q3 24 | 60.7% | 31.1% | ||
| Q2 24 | 69.8% | 31.9% | ||
| Q1 24 | 64.6% | 31.3% |
营业利润率EMBCPLPC
| Q4 25 | 31.9% | 6.8% | ||
| Q3 25 | 21.4% | 7.4% | ||
| Q2 25 | 31.8% | 10.1% | ||
| Q1 25 | 24.3% | 8.8% | ||
| Q4 24 | 11.0% | 10.5% | ||
| Q3 24 | 9.2% | 7.1% | ||
| Q2 24 | 20.5% | 8.1% | ||
| Q1 24 | 13.6% | 8.2% |
净利率EMBCPLPC
| Q4 25 | 16.9% | 4.9% | ||
| Q3 25 | 10.0% | 1.5% | ||
| Q2 25 | 15.4% | 7.5% | ||
| Q1 25 | 9.1% | 7.8% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | 5.1% | 5.2% | ||
| Q2 24 | 5.4% | 6.8% | ||
| Q1 24 | 10.1% | 6.8% |
每股收益（稀释后）EMBCPLPC
| Q4 25 | $0.74 | $1.72 | ||
| Q3 25 | $0.44 | $0.53 | ||
| Q2 25 | $0.78 | $2.56 | ||
| Q1 25 | $0.40 | $2.33 | ||
| Q4 24 | $0.00 | $2.13 | ||
| Q3 24 | $0.24 | $1.54 | ||
| Q2 24 | $0.25 | $1.89 | ||
| Q1 24 | $0.50 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | — |
| 总债务越低越好 | — | $38.3M |
| 股东权益账面价值 | $-613.1M | $475.5M |
| 总资产 | $1.1B | $653.6M |
| 负债/权益比越低杠杆越低 | — | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资EMBCPLPC
| Q4 25 | $201.3M | — | ||
| Q3 25 | $225.5M | — | ||
| Q2 25 | $230.6M | — | ||
| Q1 25 | $209.3M | — | ||
| Q4 24 | $210.0M | — | ||
| Q3 24 | $267.5M | — | ||
| Q2 24 | $275.1M | — | ||
| Q1 24 | $299.8M | — |
总债务EMBCPLPC
| Q4 25 | — | $38.3M | ||
| Q3 25 | $1.4B | $36.0M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $29.1M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | $1.6B | $27.2M | ||
| Q2 24 | — | $31.6M | ||
| Q1 24 | — | $55.0M |
股东权益EMBCPLPC
| Q4 25 | $-613.1M | $475.5M | ||
| Q3 25 | $-650.6M | $466.3M | ||
| Q2 25 | $-669.6M | $460.7M | ||
| Q1 25 | $-736.2M | $435.8M | ||
| Q4 24 | $-768.8M | $422.3M | ||
| Q3 24 | $-738.3M | $429.0M | ||
| Q2 24 | $-763.7M | $416.2M | ||
| Q1 24 | $-769.6M | $413.4M |
总资产EMBCPLPC
| Q4 25 | $1.1B | $653.6M | ||
| Q3 25 | $1.1B | $644.6M | ||
| Q2 25 | $1.2B | $631.5M | ||
| Q1 25 | $1.1B | $592.5M | ||
| Q4 24 | $1.1B | $573.9M | ||
| Q3 24 | $1.3B | $592.0M | ||
| Q2 24 | $1.3B | $572.6M | ||
| Q1 24 | $1.2B | $586.1M |
负债/权益比EMBCPLPC
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $11.8M |
| 自由现金流率自由现金流/营收 | 6.4% | 6.8% |
| 资本支出强度资本支出/营收 | 0.2% | 5.9% |
| 现金转化率经营现金流/净利润 | 0.39× | 2.60× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $33.3M |
8季度趋势，按日历期对齐
经营现金流EMBCPLPC
| Q4 25 | $17.2M | $21.9M | ||
| Q3 25 | $84.0M | $18.9M | ||
| Q2 25 | $81.2M | $26.9M | ||
| Q1 25 | $31.8M | $5.7M | ||
| Q4 24 | $-5.3M | $24.1M | ||
| Q3 24 | $26.6M | $9.4M | ||
| Q2 24 | $-2.1M | $28.3M | ||
| Q1 24 | $24.3M | $5.8M |
自由现金流EMBCPLPC
| Q4 25 | $16.6M | $11.8M | ||
| Q3 25 | $76.7M | $8.3M | ||
| Q2 25 | $80.8M | $18.6M | ||
| Q1 25 | $31.7M | $-5.3M | ||
| Q4 24 | $-6.8M | $20.6M | ||
| Q3 24 | — | $5.8M | ||
| Q2 24 | $-11.8M | $24.6M | ||
| Q1 24 | $20.9M | $1.8M |
自由现金流率EMBCPLPC
| Q4 25 | 6.4% | 6.8% | ||
| Q3 25 | 29.1% | 4.7% | ||
| Q2 25 | 27.3% | 10.9% | ||
| Q1 25 | 12.2% | -3.6% | ||
| Q4 24 | -2.6% | 12.3% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | -4.3% | 17.7% | ||
| Q1 24 | 7.3% | 1.3% |
资本支出强度EMBCPLPC
| Q4 25 | 0.2% | 5.9% | ||
| Q3 25 | 2.8% | 6.0% | ||
| Q2 25 | 0.1% | 4.9% | ||
| Q1 25 | 0.0% | 7.4% | ||
| Q4 24 | 0.6% | 2.1% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 3.6% | 2.7% | ||
| Q1 24 | 1.2% | 2.8% |
现金转化率EMBCPLPC
| Q4 25 | 0.39× | 2.60× | ||
| Q3 25 | 3.18× | 7.21× | ||
| Q2 25 | 1.78× | 2.12× | ||
| Q1 25 | 1.35× | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | 1.82× | 1.22× | ||
| Q2 24 | -0.14× | 3.02× | ||
| Q1 24 | 0.84× | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
PLPC
暂无分部数据
